BridgeBio Pharma Inc (BBIO)
23.42
+0.18
(+0.77%)
USD |
NASDAQ |
Nov 22, 16:00
23.44
+0.02
(+0.09%)
Pre-Market: 20:00
BridgeBio Pharma Cash from Operations (Quarterly): -180.57M for Sept. 30, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -180.57M |
| June 30, 2024 | 74.70M |
| March 31, 2024 | -219.54M |
| December 31, 2023 | -124.82M |
| September 30, 2023 | -145.23M |
| June 30, 2023 | -113.35M |
| March 31, 2023 | -144.32M |
| December 31, 2022 | -93.24M |
| September 30, 2022 | -135.16M |
| June 30, 2022 | -30.45M |
| March 31, 2022 | -160.64M |
| December 31, 2021 | -133.90M |
| September 30, 2021 | -121.56M |
| June 30, 2021 | -91.71M |
| Date | Value |
|---|---|
| March 31, 2021 | -150.76M |
| December 31, 2020 | -96.26M |
| September 30, 2020 | -131.68M |
| June 30, 2020 | -87.85M |
| March 31, 2020 | -83.92M |
| December 31, 2019 | -76.20M |
| September 30, 2019 | -50.00M |
| June 30, 2019 | -68.25M |
| March 31, 2019 | -59.14M |
| December 31, 2018 | -46.41M |
| September 30, 2018 | -38.32M |
| June 30, 2018 | -33.96M |
| March 31, 2018 | -17.95M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-219.54M
Minimum
Mar 2024
74.70M
Maximum
Jun 2024
-112.32M
Average
-123.19M
Median
Cash from Operations (Quarterly) Benchmarks
| Pfizer Inc | 6.714B |
| Alnylam Pharmaceuticals Inc | 43.71M |
| Vertex Pharmaceuticals Inc | 1.370B |
| PTC Therapeutics Inc | -76.99M |
| Bristol-Myers Squibb Co | 5.591B |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 38.23M |
| Cash from Financing (Quarterly) | 0.707M |
| Free Cash Flow | -456.32M |
| Free Cash Flow Per Share (Quarterly) | -0.967 |
| Free Cash Flow to Equity (Quarterly) | -184.02M |
| Free Cash Flow Yield | -10.69% |